Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial.

Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, Mathou N, Stefanidis G, Rekoumis G, Vienna E, Tzourmakliotis D, Raptis SA

Gastrointestinal endoscopy1 Apr 2002Cited by 56 (Europe PMC)

PMID11923756DOI10.1067/mge.2002.122614PepBankPUB-11923756

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
After ERCP, pancreatitis occurred in 11/112 octreotide patients (9.8%) versus 8/113 hydrocortisone patients (7.1%); the overall comparison had p = 0.32.
In plain wordsAfter ERCP, pancreatitis occurred in 9.8% with octreotide versus 7.1% with hydrocortisone; the overall comparison was not significant.
Peptide
Octreotide
Outcome
IncreasePancreatitis versus hydrocortisone
Study
n: not reported in source
Comparator
Hydrocortisone
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 microg · subcutaneousAs given in this study (human).
Measurements
Post-ERCP pancreatitis
9.8%
octreotide group, 11 of 112
Post-ERCP pancreatitis
7.1%
hydrocortisone group, 8 of 113
Source sentences
Summary
Pancreatitis was observed in 11 of 112 patients (9.8%) in Group 1, 8 of 113 (7.1%) patients in Group 2, and in 15 of 115 (13.0%) patients in Group 3 (p = 0.32).
2 context sentences(design, population, supporting numbers)
Summary · context
Three hundred fifty-four patients were entered in to a multicenter randomized controlled trial of 100 microg subcutaneous octreotide (Group 1) versus 100 mg intravenous hydrocortisone (Group 2) versus normal saline solution as placebo (Group 3).
Summary · context
All medications were administered approximately 30 minutes before the procedure.
Report a problemFND-1192375601
02HumanRandomized controlled trialEfficacy outcome
After ERCP, pancreatitis occurred in 11/112 octreotide patients (9.8%) versus 15/115 placebo patients (13.0%); the overall comparison had p = 0.32.
In plain wordsAfter ERCP, pancreatitis occurred in 9.8% with octreotide versus 13.0% with placebo; the overall comparison was not significant.
Peptide
Octreotide
Outcome
DecreasePancreatitis versus placebo
Study
n: not reported in source
Comparator
Normal saline placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 microg · subcutaneousAs given in this study (human).
Measurements
Post-ERCP pancreatitis
9.8%
octreotide group, 11 of 112
Post-ERCP pancreatitis
13%
placebo group, 15 of 115
Source sentences
Summary
Pancreatitis was observed in 11 of 112 patients (9.8%) in Group 1, 8 of 113 (7.1%) patients in Group 2, and in 15 of 115 (13.0%) patients in Group 3 (p = 0.32).
2 context sentences(design, population, supporting numbers)
Summary · context
Three hundred fifty-four patients were entered in to a multicenter randomized controlled trial of 100 microg subcutaneous octreotide (Group 1) versus 100 mg intravenous hydrocortisone (Group 2) versus normal saline solution as placebo (Group 3).
Summary · context
All medications were administered approximately 30 minutes before the procedure.
Report a problemFND-1192375602
03HumanRandomized controlled trialEfficacy outcome
After ERCP, mean hospitalization was 3.6 (SD 1.6) days with octreotide versus 2.9 (0.6) with hydrocortisone; groups were similar overall (p = 0.13).
In plain wordsAfter ERCP, hospitalization was similar overall, with 3.6 days for octreotide versus 2.9 days for hydrocortisone.
Peptide
Octreotide
Outcome
IncreaseHospitalization versus hydrocortisone
Study
n: not reported in source
Comparator
Hydrocortisone
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
100 microg · subcutaneousAs given in this study (human).
Measurements
Mean length of hospitalization
3.6 days
octreotide group; SD 1.6
Mean length of hospitalization
2.9 days
hydrocortisone group; SD 0.6
Source sentences
Summary
The mean length of hospitalization in days was similar in all 3 groups: mean (SD) for Groups 1, 2, and 3 were, respectively, 3.6 (1.6) versus 2.9 (0.6) versus 4.3 (1.8) (p = 0.13).
2 context sentences(design, population, supporting numbers)
Summary · context
Three hundred fifty-four patients were entered in to a multicenter randomized controlled trial of 100 microg subcutaneous octreotide (Group 1) versus 100 mg intravenous hydrocortisone (Group 2) versus normal saline solution as placebo (Group 3).
Summary · context
All medications were administered approximately 30 minutes before the procedure.
Report a problemFND-1192375603
04HumanRandomized controlled trialEfficacy outcome
After ERCP, mean hospitalization was 3.6 (SD 1.6) days with octreotide versus 4.3 (1.8) with placebo; groups were similar overall (p = 0.13).
In plain wordsAfter ERCP, hospitalization was similar overall, with 3.6 days for octreotide versus 4.3 days for placebo.
Peptide
Octreotide
Outcome
DecreaseHospitalization versus placebo
Study
n: not reported in source
Comparator
Normal saline placebo
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
100 microg · subcutaneousAs given in this study (human).
Measurements
Mean length of hospitalization
3.6 days
octreotide group; SD 1.6
Mean length of hospitalization
4.3 days
placebo group; SD 1.8
Source sentences
Summary
The mean length of hospitalization in days was similar in all 3 groups: mean (SD) for Groups 1, 2, and 3 were, respectively, 3.6 (1.6) versus 2.9 (0.6) versus 4.3 (1.8) (p = 0.13).
2 context sentences(design, population, supporting numbers)
Summary · context
Three hundred fifty-four patients were entered in to a multicenter randomized controlled trial of 100 microg subcutaneous octreotide (Group 1) versus 100 mg intravenous hydrocortisone (Group 2) versus normal saline solution as placebo (Group 3).
Summary · context
All medications were administered approximately 30 minutes before the procedure.
Report a problemFND-1192375604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.